基于前瞻性队列研究评估高危HPV分型检测在宫颈癌筛查中的作用
2017年6—7月在河南省济源市下冶镇招募21~64岁女性3254人建立前瞻性宫颈癌筛查队列,2741人纳入统计分析。基线HR-HPV阳性对CIN2及以上病变的灵敏度和特异度分别为89.16%和85.74%,HPV 16/18阳性分别为43.37%和97.67%。HPV 16/18阳性女性4年累积绝对风险最高(36.73%),其次为其他HR-HPV阳性(10.70%),HR-HPV阴性最低(0.39%)。
要点
- 基线HR-HPV阳性对CIN2及以上病变灵敏度89.16%、特异度85.74%。
- HPV 16/18阳性4年累积CIN2及以上风险36.73%,其他HR-HPV阳性10.70%,HR-HPV阴性0.39%。
- HR-HPV分型检测可为个体风险分层提供依据,可考虑作为有效筛查方法。
核心结论
- HR-HPV分型检测在宫颈癌筛查中对CIN2及以上病变具有较高的灵敏度和特异度,能够为个体发生CIN2及以上病变的风险提供科学分层依据以指导后续管理。
- HR-HPV分型检测可考虑作为一种有效的宫颈癌筛查方法。
研究设计与样本
- 2017年6—7月在河南省济源市下冶镇招募21~64岁身体状况良好的3254名女性建立前瞻性宫颈癌筛查队列。
- 基线筛查采集宫颈脱落细胞标本进行HR-HPV分型检测和液基细胞学检测,之后进行3年随访。
- 第1年和第2年随访行细胞学检测,第3年随访进行HR-HPV分型检测和细胞学检测。
- 符合转诊条件的女性转诊阴道镜检查,必要时进行宫颈活检及组织病理学诊断,以组织病理学诊断为CIN2及以上作为终点事件。
- 2741人纳入统计分析。
主要发现
- 基线HR-HPV分型检测HR-HPV阳性453人(16.53%),其中HPV 16/18阳性98人(3.58%),其他HR-HPV阳性355人(12.95%)。
- 研究期间共诊断出CIN2及以上患者83例。
- 基线HR-HPV阳性对CIN2及以上病变的灵敏度和特异度分别为89.16%(95% CI:80.66%~94.19%)和85.74%(95% CI:84.36%~87.02%)。
- HPV 16/18阳性对CIN2及以上病变的灵敏度和特异度分别为43.37%(95% CI:33.24%~54.09%)和97.67%(95% CI:97.02%~98.18%)。
- 4年内CIN2及以上累积绝对风险HPV 16/18阳性组最高(36.73%,95% CI:27.85%~46.62%),其他HR-HPV阳性组为10.70%(95% CI:7.87%~14.38%),HR-HPV阴性组最低(0.39%,95% CI:0.19%~0.76%)。
关键数值与推荐
- 基线HR-HPV阳性对CIN2及以上病变灵敏度89.16%(95% CI:80.66%~94.19%),特异度85.74%(95% CI:84.36%~87.02%)。
- HPV 16/18阳性对CIN2及以上病变灵敏度43.37%(95% CI:33.24%~54.09%),特异度97.67%(95% CI:97.02%~98.18%)。
- 4年累积绝对风险:HPV 16/18阳性组36.73%(95% CI:27.85%~46.62%),其他HR-HPV阳性组10.70%(95% CI:7.87%~14.38%),HR-HPV阴性组0.39%(95% CI:0.19%~0.76%)。
临床怎么用
- HR-HPV分型检测可考虑作为一种有效的宫颈癌筛查方法。
- HR-HPV分型检测可为个体发生CIN2及以上病变的风险提供科学分层依据,指导后续管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical performance of high-risk human papillomavirus (HR-HPV) genotyping in cervical cancer screening. Methods: Between June and July 2017, a prospective cervical cancer screening cohort was established in Xiaye Town, Jiyuan City, Henan Province, China by recruiting 3 254 women aged 21 to 64 years. At baseline screening, cervical exfoliated cell specimens were collected for HR-HPV genotyping and liquid-based cytology testing. Follow-ups were conducted over a 3-year period, with cytology testing in the first and second years and both HR-HPV genotyping and cytology testing in the third year. Women meeting the referral criteria were referred for colposcopy, with cervical biopsy and histopathological diagnosis performed as necessary. The endpoint was defined as cervical intraepithelial neoplasia grade 2 (CIN2) or higher confirmed by histopathological diagnosis. The sensitivity and specificity for detecting CIN2 or higher lesions of HR-HPV genotyping were calculated, as well as the cumulative risk of developing CIN2 or higher lesions over the 4-year study period in women with different baseline HR-HPV genotyping results. Results: A total of 2 741 women were included in the statistical analysis. Baseline HR-HPV genotyping detected 453 HR-HPV positive cases (16.53%), including 98 HPV 16/18 positive cases (3.58%) and 355 other HR-HPV positive cases (12.95%). During the 4-year period, 83 cases of CIN2 or higher were diagnosed. The sensitivity and specificity of baseline HR-HPV positivity for CIN2 or higher were 89.16% (95% CI: 80.66%-94.19%) and 85.74% (95% CI: 84.36%-87.02%), respectively. The corresponding rates for HPV 16/18 positivity were 43.37% (95% CI: 33.24%-54.09%) and 97.67% (95% CI: 97.02%-98.18%). The 4-year cumulative absolute risk of CIN2 or higher was highest in the HPV 16/18 positive group (36.73%, 95% CI: 27.85%-46.62%), followed by other HR-HPV positive groups (10.70%, 95% CI: 7.87%-14.38%), and the HR-HPV negative group was the lowest (0.39%, 95% CI: 0.19%-0.76%). Conclusions: HR-HPV genotyping testing exhibits high sensitivity and specificity for detecting CIN2 or higher lesions in cervical cancer screening. It also provides a scientific basis for stratifying the individual risk of developing CIN2 or higher lesions to guide subsequent management. Therefore, the HR-HPV genotyping testing can be considered as an effective method for cervical cancer screening. 目的: 评估高危人乳头瘤病毒(HR-HPV)分型检测在宫颈癌筛查中的价值。 方法: 2017年6—7月在河南省济源市下冶镇招募21~64岁身体状况良好的3 254名女性建立前瞻性宫颈癌筛查队列。基线筛查时,采集宫颈脱落细胞标本进行HR-HPV分型检测和液基细胞学检测。之后进行3年随访,第1年和第2年随访行细胞学检测,第3年随访进行HR-HPV分型检测和细胞学检测。符合转诊条件的女性转诊阴道镜检查,必要时进行宫颈活检及组织病理学诊断,以组织病理学诊断为宫颈上皮内瘤变2级(CIN2)及以上作为终点事件。计算HR-HPV分型检测对CIN2及以上病变的灵敏度、特异度,以及不同基线HR-HPV分型检测结果女性4年研究期间发生CIN2及以上病变的累积风险。 结果: 2 741人纳入统计分析。基线HR-HPV分型检测,HR-HPV阳性453人(16.53%),HPV 16/18阳性98人(3.58%),其他HR-HPV阳性355人(12.95%)。在研究期间,共诊断出CIN2及以上患者83例,基线HR-HPV阳性对CIN2及以上病变的灵敏度和特异度分别为89.16%(95% CI:80.66%~94.19%)和85.74%(95% CI:84.36%~87.02%),HPV 16/18阳性对CIN2及以上病变的灵敏度和特异度分别为43.37%(95% CI:33.24%~54.09%)和97.67%(95% CI:97.02%~98.18%)。HPV 16/18阳性女性4年内CIN2及以上累积绝对风险值最高(36.73%,95% CI:27.85%~46.62%),其次是其他HR-HPV阳性女性(10.70%,95% CI:7.87%~14.38%),HR-HPV阴性女性的累积绝对风险值最低(0.39%,95% CI:0.19%~0.76%)。 结论: HR-HPV分型检测在宫颈癌筛查中对CIN2及以上病变具有较高的灵敏度和特异度,同时能够为个体发生CIN2及以上病变的风险提供科学分层依据,指导后续管理。HR-HPV分型检测可作为一种有效的宫颈癌筛查方法。.
引用
- Wang H, Liu Y, Xu HF, et al. [Evaluation of high-risk HPV genotyping detection in cervical cancer screening based on a prospective cohort study]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40375594. doi:10.3760/cma.j.cn112152-20240219-00079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。